Treatment Intensification in Localized Prostate Cancer: What Route with What Car?
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 April 2024 | Viewed by 3977
Special Issue Editors
Interests: prostate cancer; radiotherapy; bladder cancer
Interests: prostate cancer; radiotherapy; bladder cancer
Special Issue Information
Dear Colleagues,
For patients with prostate cancer (PCa) treated with radiotherapy, support for intensification with abiraterone and androgen deprivation therapy (ADT) is the new standard of care based on the STAMPEDE trial. Nevertheless, appropriately intensified radiotherapy could be complementary or even an alternative to systemic intensification for selected patients. Evidence from contemporary randomized trials in highrisk prostate cancer shows that the intensification of prostate radiotherapy—via brachytherapy (ASCENDE-RT), intraprostatic boost (FLAME), or elective pelvic irradiation (POPRT)—results in 5 yr metastasis-free survival (MFS) of 90–95% with ADT alone. Results from ongoing trials evaluating the same strategy in the post-operative setting are awaited. The aim of this Topic Issue is to review evidence regarding treatment intensification in localized PCa, describing rationale, oncological outcomes, tolerance and perspectives.
Dr. Paul Sargos
Dr. Igor Latorzeff
Dr. Vedang Murthy
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- hormonal treatment
- radiotherapy
- pelvic radiotherapy
- brachytherapy
- post-operative radiotherapy